The zone's "Free Trade Circle" column covered the National Center for Technology Transfer in Biomedicine, with Eynos appearing as one of the case studies; the report cites revenue growth ahead of the company's own plan.
This page summarises a media report about Eynos. Quoted wording — including terms such as "breakthrough", "on par with", "first" or "unique" — is the original reporter's language and is not a performance claim by the company. Product performance is defined by the manual and the measured data. All products are for research use only (RUO) and are not intended for diagnostic or therapeutic use.
The article is about the centre's translation model and lists several resident companies. The figures quoted for Eynos are the reporter's, based on information supplied at the time of interview, and are not audited financial statements.
The passage on CD3 isolation reagent performance refers to internal validation; product specifications and measured data are published on the individual product pages.
The full report is published in Chinese: 中文原文. This page is an English summary prepared by Eynos.
Tell us your cell type, sample source and downstream assay — we will suggest an isolation route, a culture condition and the matching catalogue numbers.